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 In recent years, stem cell research has 
emerged as one of the most exciting areas 
of scientific discovery and medical prom-
ise. Human embryonic stem cells capture 
the imagination because they are immor-
tal and have an almost unlimited devel-
opmental potential. After many months 
of growth in culture dishes, these remark-
able cells maintain the ability to form cells 
ranging from muscle to nerve to blood—
potentially any cell type that makes up 
the human body. The proliferative and 
developmental potential of human em-
bryonic stem cells promises an essentially 
unlimited supply of specific cell types for 
basic research and transplantation thera-
pies for diseases, ranging from heart dis-
ease to Parkinson’s disease to leukemia. 
Stem cells can also be used to study an 
individual’s disease progression in vitro, 
opening up opportunities for personal-
ized therapeutics and pharmaceuticals. 
 The early concept about how to har-
ness stem cells was simplicity itself: har-
vest the unformed cells from embryos 
and inject them into needy recipients. 
The stem cells would then start rebuild-
ing damaged hearts, pushing cancer to re-
mission, or healing injured spinal cords. 
Heart disease, ALS, Parkinson’s disease, 
and type I diabetes would all be swept 
away under the tidal wave of the stem 
cell cure. However, similar to a foreign 
kidney or heart transplant, injection of 
foreign cells would likely cause immuno-
logical rejection by the body. Destruction 
of human embryos for scientific research 
also poses numerous ethical challenges. 
 In 2006, researchers in Japan lead by 
Dr. Shinya Yamanaka from Kyoto Univer-
sity had an ingenious yet simple scientific 
breakthrough. Their discovery, which 
won the Nobel Prize in Physiology or 
Medicine, was predicated on reprogram-
ming mature somatic cells, such as skin 
fibroblasts, into embryonic-like stem cells 
by using viruses to add only four genes 
into the fibroblast’s nucleus. These re-
programed cells or “induced pluripotent 
stem cells,” iPS cells, were shown to dif-
ferentiate into nearly every cell type in 
the body and evade the perils of rejection 
since the cells were the patient’s own. iPS 
cells essentially eliminate all ethical chal-
lenges surrounding the derivation of stem 
cells because no embryos are destroyed. 
 Numerous studies since have greatly 
advanced our understanding of the biol-
ogy that regulates stem cell differentia-
tion and the stem cell microenvironment. 
However, in order to realize the clinical 
promise of stem cells, our fundamental 
knowledge of stem cell biology must be 
translated into suitable applications. Dr. 
Todd McDevitt, Associate Professor in the 
Wallace H. Coulter Department of Bio-
medical Engineering and Director of the 
Stem Cell Engineering Center, argues that 
the nascent field of stem cell engineering 
will be increasingly necessary to realize 
the scientific community’s envisioned 
goals of stem cell based therapeutics, di-
agnostics and drug discovery platforms. 
 Engineering conditions for iPS cells 
to differentiate homogeneously into a 
specific cell type is currently difficult. One 
study demonstrated that although global 
gene expression of iPS cells looks amaz-
ingly similar to embryonic stem cells, 
there are distinct regions in the genetic 
code of iPS cells that do not get repro-
grammed properly. In those regions, iPS 
cells’ genomes still resembled the tissues 
from which they came from, suggesting 
that the cells had not been fully set back 
to the embryonic stage. Consequently, iPS 
cell cultures can become contaminated 
with other cell types, which do not have 
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 Manually sorting these stem cells 
is time consuming and difficult; using 
chemical approaches can damage the 
DNA inside. To address the problem, 
post-doctoral fellow Dr. Ankur Singh and 
Dr. McDevitt, in collaboration with Pro-
fessor Andres Garcia have demonstrated 
a tunable process that separates cells ac-
cording to the degree to which they ad-
here to a substrate inside a tiny microflu-
idic device.
 The adhesion properties of the human 
iPS cells differ significantly from those of 
the cells with which they are mixed, al-
lowing the potentially-therapeutic cells 
to be separated to as much as 99 percent 
purity. The high-throughput separation 
process, which takes less than 10 min-
utes to perform, does not rely on labeling 
technologies such as antibodies. Because 
it allows separation of intact cell colonies, 
it avoids damaging the cells, allowing a 
cell survival rate greater than 80 percent. 
The resulting cells retain normal tran-
scriptional profiles and differentiation 
potential. Using inexpensive, disposable 
“cassettes,” the microfluidic system could 
be scaled up to filter increased volumes of 
cells and to allow the feasible possibility 
of commercialization and manufacture of 
stem cell therapies for humans. 
 The Georgia Tech researchers applied 
their new understanding of the adhesive 
properties of human iPS cells to develop a 
quick, efficient method for isolating these 
medically important cells. Their work, 
published in the journal  Nature Methods 
[1],  represents an innovative conversion 
of basic stem cell biology, biomaterials, 
and engineering into a strategy with ther-
apeutic potential. During testing, iPS cell 
cultures were first allowed to attach to the 
microfluidic device before being subject-
ed to the flow of buffer fluid. Cells with 
a lower adhesive strength detached from 
the substrate at lower flow rates. By vary-
ing the flow rate, the researchers were 
able to separate specific types of cells with 
high purity from mixtures in which those 
cells accounted for only a few percent of 
the total. 
 Since their discovery, iPS cells have 
captured the imagination of researchers 
and clinicians seeking to develop patient-
specific therapies. Reprogramming adult 
tissues to embryonic-like states has count-
less prospective applications in regen-
erative medicine, drug development, and 
basic research on stem cells and devel-
opmental processes. To this point, more 
than 2100 research papers on iPS cells 
have been published since 2006, indicat-
ing a highly active and rapidly develop-
ing research field. Purification of iPS cells 
marks a significant achievement in realiz-
ing the promise of stem cells for therapies 
and scientific advancement. While much 
remains to be learned and significant 
challenges remain in iPS cell research, 
the development of reprogramming tech-
niques represents a breakthrough that 
will ultimately open many new avenues 
of research and therapy.
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